September 11th 2023
Characteristics including Ogata score and phenotypic aberrancies may correlate with mutational patterns that are predictive of treatment response in patients with myelodysplastic syndrome.
September 8th 2023
Chemo/Immunotherapy Confers Greater Therapy-Related MDS/AML Risk in Survivors
August 3rd 2023Investigators note that although therapy-related myelodysplastic syndromes or acute myeloid leukemia are not common, efforts to reduce treatment-associated toxicity in survivors of lymphoid neoplasms are needed given the poor prognosis associated with the diagnosis.
Ropeginterferon Is NCCN-Recommended Preferred Therapy in Polycythemia Vera
May 29th 2023Ropeginterferon alfa-2b-njft has been moved to preferred status in the National Comprehensive Cancer Network guidelines for polycythemia vera based on data supporting the agent’s superior efficacy and safety in high- and low-risk populations.
Momelotinib May Set New Standard in Myelofibrosis, Expert Says
February 14th 2023“Transfusion independence is the key to my excitement [with] momelotinib as a drug. I will likely use it in most patients in the second-line setting,” says an expert from the University of Texas MD Anderson Cancer Center.
Reduction in Transfusion Dependency Observed With Low-Dose Lenalidomide for Myelodysplastic Syndrome
December 12th 2022Findings from the final analysis phase 3 SINTRA-REV trial indicated that lenalidomide lowered the risk of transfusion dependency when administered at a low dose in patients with myelodysplastic syndrome.
Luspatercept-aamt Yields Improved RBC-TI and Hemoglobin Increase Vs Epoetin Alfa in MDS
November 1st 2022Among adult patients with low- or intermediate-risk myelodysplastic syndromes requiring red blood cell transfusions, luspatercept-aamt improved red blood cell transfusion independence with concurrent hemoglobin increase compared with epoetin alfa.
Targeting CD117 With JSP191, TBI, and Fludarabine Appears Safe and Efficacious in MDS/AML
April 29th 2022JSP191 plus fludarabine and low-dose total body radiation to target CD117 was a safe strategy to induce facilitation of full donor myeloid chimerism and clear minimal residual disease in older patients with myelodysplastic syndrome and acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.
Allo-HCT From Younger Matched Unrelated Donors Yields High DFS, Low Recurrence in MDS
February 22nd 2022Patients who underwent allogeneic hematopoietic cell transplantation using younger matched unrelated donors had a better disease-free survival compared who those who used older matched sibling donors.